Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Socioeconomic disparities in prehospital factors and survival after out-of-hospital cardiac arrest

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Variations in knowledge, awareness and treatment of hypertension and stroke risk by country income level

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Global longitudinal strain predicts cardiovascular events after coronary artery bypass grafting

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Valve regurgitation in patients surviving endocarditis and the subsequent risk of heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Higher habitual flavonoid intakes are associated with a lower risk of peripheral artery disease hospitalizations

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Flavonoid intake and its association with atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Thromboembolic events related to atrial fibrillation during the COVID-19 epidemic in Denmark

    Research output: Contribution to journalLetterpeer-review

  5. An overview and update on the epidemiology of flavonoid intake and cardiovascular disease risk

    Research output: Contribution to journalReviewpeer-review

  • Anthony P Carnicelli
  • Sana M Al-Khatib
  • Denis Xavier
  • Frederik Dalgaard
  • Peter D Merrill
  • Daniel M Wojdyla
  • Basil S Lewis
  • Michael Hanna
  • John H Alexander
  • Renato D Lopes
  • Lars Wallentin
  • Christopher B Granger
View graph of relations

AIMS: The ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial randomised patients with atrial fibrillation at risk of stroke to apixaban or warfarin. We sought to describe patients from ARISTOTLE who prematurely permanently discontinued study drug.

METHODS/RESULTS: We performed a posthoc analysis of patients from ARISTOTLE who prematurely permanently discontinued study drug during the study or follow-up period. Discontinuation rates and reasons for discontinuation were described. Death, thromboembolism (stroke, transient ischaemic attack, systemic embolism), myocardial infarction and major bleeding rates were stratified by ≤30 days or >30 days after discontinuation. A total of 4063/18 140 (22.4%) patients discontinued study drug at a median of 7.3 (2.2, 15.2) months after randomisation. Patients with discontinuation were more likely to be female and had a higher prevalence of cardiovascular disease, diabetes, renal impairment and anaemia. Premature permanent discontinuation was more common in those randomised to warfarin than apixaban (23.4% vs 21.4%; p=0.002). The most common reasons for discontinuation were patient request (46.1%) and adverse event (34.9%), with no significant difference between treatment groups. The cumulative incidence of clinical events ≤30 days after premature permanent discontinuation for all-cause death, thromboembolism, myocardial infarction, and major bleeding was 5.8%, 2.6%, 0.9%, and 3.0%, respectively. No significant difference was seen between treatment groups with respect to clinical outcomes after discontinuation.

CONCLUSION: Premature permanent discontinuation of study drug in ARISTOTLE was common, less frequent in patients receiving apixaban than warfarin and was followed by high 30-day rates of death, thromboembolism and major bleeding. Initiatives are needed to reduce discontinuation of oral anticoagulation.

Original languageEnglish
JournalHeart (British Cardiac Society)
Volume107
Issue number9
Pages (from-to)713-720
Number of pages8
ISSN1355-6037
DOIs
Publication statusPublished - May 2021

    Research areas

  • atrial fibrillation, atrial flutter, pharmacology, stroke

ID: 62107569